912806-16-7 Usage
General Description
The chemical compound "4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide hydrochloride" is a hydrochloride salt of a pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide derivative. It is a derivative of the pyrrolo[2,1-f][1,2,4]triazine class, with a methyl and propyl substitution on the nitrogen and carbon atoms, respectively. It also contains a cyclopropylamino carbonyl group and a methylphenylamino group. 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide hydrochloride may have potential pharmaceutical applications due to its molecular structure and properties, but further research and testing would be necessary to determine its specific uses and effects.
Check Digit Verification of cas no
The CAS Registry Mumber 912806-16-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,8,0 and 6 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 912806-16:
(8*9)+(7*1)+(6*2)+(5*8)+(4*0)+(3*6)+(2*1)+(1*6)=157
157 % 10 = 7
So 912806-16-7 is a valid CAS Registry Number.
912806-16-7Relevant articles and documents
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
-
Page/Page column 26, (2010/11/24)
Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.
